Determining the Anti-Tumoral Activity of BAY 3375968: An Afucosylated Anti-CCR8 Antibody Which Depletes Activated Intratumoral Tregs via the Innate Immune System to Kill Cancer

Time: 1:30 pm
day: Day One


  • Understanding Treg promotion of cancer by suppressing the function of CD8+ and CD4+ T cells in the TME to hamper the efficacy of immune checkpoint inhibitors
  • Harnessing BAY 3375968 by simultaneous binding to CCR8 on Tregs and to Fcγ receptors on effector cells to induce ADCC and ADCP to mediate the cancer kills
  • Utilising assays and preclinical models to characterize the MOA of anti-tumour action of BAY 3375968 and mouse CCR8 surrogate antibodies in vitro and in vivo for smooth translation to the clinic